Erik PÃ¥lsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2559926/publications.pdf

Version: 2024-02-01

44	1,270	331538	395590
papers	citations	21 h-index	33 g-index

46	46	46	2280
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A serum proteomic study of two case-control cohorts identifies novel biomarkers for bipolar disorder. Translational Psychiatry, 2022, 12, 55.	2.4	7
2	Influence of genetic variations in IL1B on brain region volumes in bipolar patients and controls. Psychiatry Research, 2021, 296, 113606.	1.7	4
3	Association of CACNA1C polymorphisms with serum BDNF levels in bipolar disorder. British Journal of Psychiatry, 2021, 218, 77-79.	1.7	11
4	Genome-wide association study of patients with a severe major depressive episode treated with electroconvulsive therapy. Molecular Psychiatry, 2021, 26, 2429-2439.	4.1	32
5	Central levels of tryptophan metabolites in subjects with bipolar disorder. European Neuropsychopharmacology, 2021, 43, 52-62.	0.3	24
6	Patient educational level and management of bipolar disorder. BJPsych Open, 2021, 7, e63.	0.3	6
7	Long-term trajectory of cognitive performance in people with bipolar disorder and controls: 6-year longitudinal study. BJPsych Open, 2021, 7, e115.	0.3	8
8	Regional lithium prescription rates and recurrence in bipolar disorder. International Journal of Bipolar Disorders, 2021, 9, 18.	0.8	8
9	Serum profiling of anorexia nervosa: A 1H NMR-based metabolomics study. European Neuropsychopharmacology, 2021, 49, 1-10.	0.3	6
10	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	1.7	20
11	Cerebrospinal fluid proteomics targeted for central nervous system processes in bipolar disorder. Molecular Psychiatry, 2021, 26, 7446-7453.	4.1	5
12	Psychoeducation for bipolar disorder and risk of recurrence and hospitalization â€“ a within-individual analysis using registry data. Psychological Medicine, 2020, 50, 1043-1049.	2.7	19
13	Characteristics of bipolar I and II disorder: A study of 8766 individuals. Bipolar Disorders, 2020, 22, 392-400.	1.1	52
14	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	1.8	22
15	CACNA1C polymorphism and brain cortical structure in bipolar disorder. Journal of Psychiatry and Neuroscience, 2020, 45, 182-187.	1.4	10
16	Long-term subjective memory after electroconvulsive therapy. BJPsych Open, 2020, 6, e26.	0.3	23
17	Executive functioning but not IQ or illness severity predicts occupational status in bipolar disorder. International Journal of Bipolar Disorders, 2020, 8, 7.	0.8	16
18	Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative. International Journal of Bipolar Disorders, 2019, 7, 20.	0.8	41

#	Article	IF	Citations
19	Classification of cognitive performance in bipolar disorder. Cognitive Neuropsychiatry, 2017, 22, 407-421.	0.7	12
20	Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. Journal of Neural Transmission, 2017, 124, 1135-1143.	1.4	19
21	Personality traits in bipolar disorder and influence on outcome. BMC Psychiatry, 2017, 17, 159.	1.1	32
22	Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder. BBA Clinical, 2016, 5, 151-158.	4.1	76
23	Polymorphisms of BDNF and CACNA1C are not associated with cognitive functioning in bipolar disorder or healthy controls. Cognitive Neuropsychiatry, 2016, 21, 271-278.	0.7	14
24	Dietary intake, resting energy expenditure, and eating behavior in women with and without polycystic ovary syndrome. Clinical Nutrition, 2016, 35, 213-218.	2.3	54
25	CACNA1Cpolymorphism and altered phosphorylation of tau in bipolar disorder. British Journal of Psychiatry, 2016, 208, 195-196.	1.7	19
26	Polymorphisms of dopamine pathway genes <scp>NRG</scp>1 and <scp>LMX</scp>1A are associated with cognitive performance in bipolar disorder. Bipolar Disorders, 2015, 17, 859-868.	1.1	23
27	Cognitive Performance and Cerebrospinal Fluid Biomarkers of Neurodegeneration: A Study of Patients with Bipolar Disorder and Healthy Controls. PLoS ONE, 2015, 10, e0127100.	1.1	38
28	Monocyte and microglial activation in patients with mood-stabilized bipolar disorder. Journal of Psychiatry and Neuroscience, 2015, 40, 250-258.	1.4	75
29	CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment. European Neuropsychopharmacology, 2015, 25, 1091-1098.	0.3	47
30	Increased brain nitric oxide levels following ethanol administration. Nitric Oxide - Biology and Chemistry, 2015, 47, 52-57.	1.2	22
31	Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment. Brain, Behavior, and Immunity, 2015, 43, 198-204.	2.0	51
32	Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. European Neuropsychopharmacology, 2015, 25, 133-140.	0.3	38
33	Cognitive Functioning in Clinically Stable Patients with Bipolar Disorder I and II. PLoS ONE, 2015, 10, e0115562.	1.1	36
34	Low neuropeptide Y in cerebrospinal fluid in bipolar patients is associated with previous and prospective suicide attempts. European Neuropsychopharmacology, 2014, 24, 1907-1915.	0.3	24
35	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
36	Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: A study of two independent cohorts. Journal of Affective Disorders, 2014, 160, 1-9.	2.0	78

#	Article	IF	Citations
37	Bloodâ€“cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment. Psychiatry Research, 2014, 217, 143-146.	1.7	36
38	Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls. BMC Psychiatry, 2013, 13, 165.	1.1	64
39	Brain nitric oxide: Regional characterisation of a real-time microelectrochemical sensor. Journal of Neuroscience Methods, 2012, 209, 13-21.	1.3	25
40	Noise benefit in prepulse inhibition of the acoustic startle reflex. Psychopharmacology, 2011, 214, 675-685.	1.5	13
41	Information processing deficits and nitric oxide signalling in the phencyclidine model of schizophrenia. Psychopharmacology, 2010, 212, 643-651.	1.5	11
42	Increased cortical nitric oxide release after phencyclidine administration. Synapse, 2009, 63, 1083-1088.	0.6	22
43	Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. European Journal of Pharmacology, 2008, 590, 212-216.	1.7	27
44	The amino acid l-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice. Psychopharmacology, 2007, 192, 9-15.	1.5	13